A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

PHASE2

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

BIOLOGICAL: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
BIOLOGICAL: Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine

GlaxoSmithKline